A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

NCT06678659 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable
Locally Advanced
Metastatic Cancers
Relapsed/Refractory Lymphomas

Interventions

DRUG: REC-1245

Sponsor

Recursion Pharmaceuticals Inc.